MYC deregulation in lymphoid tumors: Molecular mechanisms, clinical consequences and therapeutic implications

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1846, Issue 2, 2014, Pages 457-467

  Sewastianik, Tomasz ^a   Prochorec Sobieszek, Monika ^a   Chapuy, Bjoern ^b   Juszczyński, Przemysław ^a  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Burkitt lymphoma; Diffuse large B cell lymphoma; Double hit lymphoma; MYC; Targeted therapy

Indexed keywords

4 (4 CHLOROPHENYL) N (4 HYDROXYPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETAMIDE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 6 (4 CHLOROPHENYL) N ETHYL 8 METHOXY 1 METHYL 4H [1,2,4]TRIAZOLO[4,3 A][1,4]BENZODIAZEPINE 4 ACETAMIDE; ALISERTIB; BROMODOMAIN INHIBITOR; CPI 0610; MYC PROTEIN; OBATOCLAX; PALBOCICLIB; PROTEIN KINASE INHIBITOR; SGI 1776; UNCLASSIFIED DRUG;

APOPTOSIS; B CELL LYMPHOMA; BINDING AFFINITY; BIOLOGICAL ACTIVITY; BURKITT LYMPHOMA; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE; CELL METABOLISM; CYTOGENETICS; DIMERIZATION; FOLLICULAR LYMPHOMA; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE INTERACTION; GENE REARRANGEMENT; GENE TARGETING; GENETIC REGULATION; GENETIC TRANSCRIPTION; HUMAN; INTRACELLULAR SIGNALING; LARGE CELL LYMPHOMA; LETHALITY; LYMPHATIC SYSTEM TUMOR; MULTIPLE MYELOMA; NONHUMAN; ONCOGENE MYC; PLASMABLASTIC LYMPHOMA; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; REVIEW; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; LYMPHOMA, B-CELL; MOUSE; PHYSIOLOGY;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; LYMPHOMA, B-CELL; MICE; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84907764747     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.08.006     Document Type: Review

References (159)

1. Sheiness D., Bishop J.M. DNA and RNA from uninfected vertebrate cells contain nucleotide sequences related to the putative transforming gene of avian myelocytomatosis virus. J. Virol. 1979, 31:514-521.
2. Varmus H.E. The molecular genetics of cellular oncogenes. Annu. Rev. Genet. 1984, 18:553-612.
3. Dalla-Favera R., Bregni M., Erikson J., Patterson D., Gallo R.C., Croce C.M. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl. Acad. Sci. U. S. A. 1982, 79:7824-7827.
4. Taub R., Kirsch I., Morton C., Lenoir G., Swan D., Tronick S., Aaronson S., Leder P. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc. Natl. Acad. Sci. U. S. A. 1982, 79:7837-7841.
5. Adams J.M., Harris A.W., Pinkert C.A., Corcoran L.M., Alexander W.S., Cory S., Palmiter R.D., Brinster R.L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985, 318:533-538.
6. Kovalchuk A.L., Qi C.F., Torrey T.A., Taddesse-Heath L., Feigenbaum L., Park S.S., Gerbitz A., Klobeck G., Hoertnagel K., Polack A., Bornkamm G.W., Janz S., Morse H.C. Burkitt lymphoma in the mouse. J. Exp. Med. 2000, 192:1183-1190.
7. Baudino T.A., McKay C., Pendeville-Samain H., Nilsson J.A., Maclean K.H., White E.L., Davis A.C., Ihle J.N., Cleveland J.L. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 2002, 16:2530-2543.
8. Wilson A., Murphy M.J., Oskarsson T., Kaloulis K., Bettess M.D., Oser G.M., Pasche A.C., Knabenhans C., Macdonald H.R., Trumpp A. c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev. 2004, 18:2747-2763.
9. Baena E., Ortiz M., Martinez A.C., de Alboran I.M. c-Myc is essential for hematopoietic stem cell differentiation and regulates Lin(-)Sca-1(+)c-Kit(-) cell generation through p21. Exp. Hematol. 2007, 35:1333-1343.
10. Huang C.Y., Bredemeyer A.L., Walker L.M., Bassing C.H., Sleckman B.P. Dynamic regulation of c-Myc proto-oncogene expression during lymphocyte development revealed by a GFP-c-Myc knock-in mouse. Eur. J. Immunol. 2008, 38:342-349.
11. Dominguez-Sola D., Victora G.D., Ying C.Y., Phan R.T., Saito M., Nussenzweig M.C., Dalla-Favera R. The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. Nat. Immunol. 2012, 13:1083-1091.
12. Lin Y., Wong K., Calame K. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science (New York, N.Y.) 1997, 276:596-599.
13. Calado D.P., Sasaki Y., Godinho S.A., Pellerin A., Kochert K., Sleckman B.P., de Alboran I.M., Janz M., Rodig S., Rajewsky K. The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers. Nat. Immunol. 2012, 13:1092-1100.
14. Robbiani D.F., Bothmer A., Callen E., Reina-San-Martin B., Dorsett Y., Difilippantonio S., Bolland D.J., Chen H.T., Corcoran A.E., Nussenzweig A., Nussenzweig M.C. AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell 2008, 135:1028-1038.
15. Ramiro A.R., Jankovic M., Eisenreich T., Difilippantonio S., Chen-Kiang S., Muramatsu M., Honjo T., Nussenzweig A., Nussenzweig M.C. AID is required for c-myc/IgH chromosome translocations in vivo. Cell 2004, 118:431-438.
16. Balague Ponz O., Ott G., Hasserjian R.P., Elenitoba-Johnson K.S., de Leval L., de Jong D. Commentary on the WHO classification of tumors of lymphoid tissues (2008): aggressive B-cell lymphomas. J. Hematop. 2009, 2:83-87.
17. Leoncini L., Raphaël M., Stein H., Harris N.L., Jaffe E.S. Burkitt lymphoma. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 262-264. IARC, Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Varidman (Eds.).
18. Dogan A., Bagdi E., Munson P., Isaacson P.G. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am. J. Surg. Pathol. 2000, 24:846-852.
19. Boerma E.G., Siebert R., Kluin P.M., Baudis M. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge. Leuk. Off. J. Leuk. Soc. Am. Leuk. Res. Fund UK 2009, 23:225-234.
20. Neri A., Barriga F., Knowles D.M., Magrath I.T., Dalla-Favera R. Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:2748-2752.
21. Morse B., South V.J., Rothberg P.G., Astrin S.M. Somatic mutation and transcriptional deregulation of myc in endemic Burkitt's lymphoma disease: heptamer-nonamer recognition mistakes?. Mol. Cell. Biol. 1989, 9:74-82.
22. de Jong D., Balague Ponz O. The molecular background of aggressive B cell lymphomas as a basis for targeted therapy. J. Pathol. 2011, 223:274-282.
23. Leucci E., Cocco M., Onnis A., De Falco G., van Cleef P., Bellan C., van Rijk A., Nyagol J., Byakika B., Lazzi S., Tosi P., van Krieken H., Leoncini L. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J. Pathol. 2008, 216:440-450.
24. Onnis A., De Falco G., Antonicelli G., Onorati M., Bellan C., Sherman O., Sayed S., Leoncini L. Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma. PLoS One 2010, 5.
25. Salaverria I., Martin-Guerrero I., Wagener R., Kreuz M., Kohler C.W., Richter J., Pienkowska-Grela B., Adam P., Burkhardt B., Claviez A., Damm-Welk C., Drexler H.G., Hummel M., Jaffe E.S., Kuppers R., Lefebvre C., Lisfeld J., Loffler M., Macleod R.A., Nagel I., Oschlies I., Rosolowski M., Russell R.B., Rymkiewicz G., Schindler D., Schlesner M., Scholtysik R., Schwaenen C., Spang R., Szczepanowski M., Trumper L., Vater I., Wessendorf S., Klapper W., Siebert R. A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood 2014, 123:1187-1198.
26. Armitage J.O., Weisenburger D.D. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1998, 16:2780-2795.
27. Tomita N. BCL2 and MYC dual-hit lymphoma/leukemia. J. clin. exp. Hematopathology: JCEH 2011, 51:7-12.
28. Monti S., Chapuy B., Takeyama K., Rodig S.J., Hao Y., Yeda K.T., Inguilizian H., Mermel C., Currie T., Dogan A., Kutok J.L., Beroukhim R., Neuberg D., Habermann T.M., Getz G., Kung A.L., Golub T.R., Shipp M.A. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell 2012, 22:359-372.
29. Stasik C.J., Nitta H., Zhang W., Mosher C.H., Cook J.R., Tubbs R.R., Unger J.M., Brooks T.A., Persky D.O., Wilkinson S.T., Grogan T.M., Rimsza L.M. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica 2010, 95:597-603.
30. Hummel M., Bentink S., Berger H., Klapper W., Wessendorf S., Barth T.F., Bernd H.W., Cogliatti S.B., Dierlamm J., Feller A.C., Hansmann M.L., Haralambieva E., Harder L., Hasenclever D., Kuhn M., Lenze D., Lichter P., Martin-Subero J.I., Moller P., Muller-Hermelink H.K., Ott G., Parwaresch R.M., Pott C., Rosenwald A., Rosolowski M., Schwaenen C., Sturzenhofecker B., Szczepanowski M., Trautmann H., Wacker H.H., Spang R., Loeffler M., Trumper L., Stein H., Siebert R., Molecular K. Mechanisms in Malignant Lymphomas Network Project of the Deutsche, a biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N. Engl. J. Med. 2006, 354:2419-2430.
31. Aukema S.M., Siebert R., Schuuring E., van Imhoff G.W., Kluin-Nelemans H.C., Boerma E.J., Kluin P.M. Double-hit B-cell lymphomas. Blood 2011, 117:2319-2331.
32. Horn H., Ziepert M., Becher C., Barth T.F., Bernd H.W., Feller A.C., Klapper W., Hummel M., Stein H., Hansmann M.L., Schmelter C., Moller P., Cogliatti S., Pfreundschuh M., Schmitz N., Trumper L., Siebert R., Loeffler M., Rosenwald A., Ott G. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013, 121:2253-2263.
33. Dave S.S., Fu K., Wright G.W., Lam L.T., Kluin P., Boerma E.J., Greiner T.C., Weisenburger D.D., Rosenwald A., Ott G., Muller-Hermelink H.K., Gascoyne R.D., Delabie J., Rimsza L.M., Braziel R.M., Grogan T.M., Campo E., Jaffe E.S., Dave B.J., Sanger W., Bast M., Vose J.M., Armitage J.O., Connors J.M., Smeland E.B., Kvaloy S., Holte H., Fisher R.I., Miller T.P., Montserrat E., Wilson W.H., Bahl M., Zhao H., Yang L., Powell J., Simon R., Chan W.C., Staudt L.M. Molecular diagnosis of Burkitt's lymphoma. N. Engl. J. Med. 2006, 354:2431-2442.
34. Kluk M.J., Chapuy B., Sinha P., Roy A., Dal Cin P., Neuberg D.S., Monti S., Pinkus G.S., Shipp M.A., Rodig S.J. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One 2012, 7:e33813.
35. Hu S., Xu-Monette Z.Y., Tzankov A., Green T., Wu L., Balasubramanyam A., Liu W.M., Visco C., Li Y., Miranda R.N., Montes-Moreno S., Dybkaer K., Chiu A., Orazi A., Zu Y., Bhagat G., Richards K.L., Hsi E.D., Choi W.W., Zhao X., van Krieken J.H., Huang Q., Huh J., Ai W., Ponzoni M., Ferreri A.J., Zhou F., Slack G.W., Gascoyne R.D., Tu M., Variakojis D., Chen W., Go R.S., Piris M.A., Moller M.B., Medeiros L.J., Young K.H. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013, 121:4021-4031. (quiz 4250).
36. Valera A., Lopez-Guillermo A., Cardesa-Salzmann T., Climent F., Gonzalez-Barca E., Mercadal S., Espinosa I., Novelli S., Briones J., Mate J.L., Salamero O., Sancho J.M., Arenillas L., Serrano S., Erill N., Martinez D., Castillo P., Rovira J., Martinez A., Campo E., Colomo L. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica 2013, 98:1554-1562.
37. McClure R.F., Remstein E.D., Macon W.R., Dewald G.W., Habermann T.M., Hoering A., Kurtin P.J. Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am. J. Surg. Pathol. 2005, 29:1652-1660.
38. Haralambieva E., Boerma E.J., van Imhoff G.W., Rosati S., Schuuring E., Muller-Hermelink H.K., Kluin P.M., Ott G. Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am. J. Surg. Pathol. 2005, 29:1086-1094.
39. Kluin P.M., Harris N.L., Stein H., Leoncini L., Raphaël M., Campo E., Jaffe E.S. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 265-266. IARC, Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Varidman (Eds.).
40. Klapper W., Stoecklein H., Zeynalova S., Ott G., Kosari F., Rosenwald A., Loeffler M., Trumper L., Pfreundschuh M., Siebert R. German high-grade non-Hodgkin's lymphoma study, structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German high-grade non-Hodgkin's lymphoma study group (DSHNHL). Leuk. Off. J. Leuk. Soc. Am. Leuk. Res. Fund UK 2008, 22:2226-2229.
41. Savage K.J., Johnson N.A., Ben-Neriah S., Connors J.M., Sehn L.H., Farinha P., Horsman D.E., Gascoyne R.D. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009, 114:3533-3537.
42. Barrans S., Crouch S., Smith A., Turner K., Owen R., Patmore R., Roman E., Jack A. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2010, 28:3360-3365.
43. Green T.M., Young K.H., Visco C., Xu-Monette Z.Y., Orazi A., Go R.S., Nielsen O., Gadeberg O.V., Mourits-Andersen T., Frederiksen M., Pedersen L.M., Moller M.B. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2012, 30:3460-3467.
44. Johnson N.A., Savage K.J., Ludkovski O., Ben-Neriah S., Woods R., Steidl C., Dyer M.J., Siebert R., Kuruvilla J., Klasa R., Connors J.M., Gascoyne R.D., Horsman D.E. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009, 114:2273-2279.
45. Delgado M.D., Leon J. Myc roles in hematopoiesis and leukemia. Genes Cancer 2010, 1:605-616.
46. Valera A., Balague O., Colomo L., Martinez A., Delabie J., Taddesse-Heath L., Jaffe E.S., Campo E. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am. J. Surg. Pathol. 2010, 34:1686-1694.
47. Smith S.M., Anastasi J., Cohen K.S., Godley L.A. The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma. Blood Cells Mol. Dis. 2010, 45:317-323.
48. Blackwood E.M., Eisenman R.N. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science (New York, N.Y.) 1991, 251:1211-1217.
49. Dani C., Blanchard J.M., Piechaczyk M., El Sabouty S., Marty L., Jeanteur P. Extreme instability of myc mRNA in normal and transformed human cells. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:7046-7050.
50. Hann S.R., Eisenman R.N. Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Mol. Cell. Biol. 1984, 4:2486-2497.
51. Yeh E., Cunningham M., Arnold H., Chasse D., Monteith T., Ivaldi G., Hahn W.C., Stukenberg P.T., Shenolikar S., Uchida T., Counter C.M., Nevins J.R., Means A.R., Sears R. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat. Cell Biol. 2004, 6:308-318.
52. Gregory M.A., Qi Y., Hann S.R. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J. Biol. Chem. 2003, 278:51606-51612.
53. Zhang Y., Wang Z., Li X., Magnuson N.S. Pim kinase-dependent inhibition of c-Myc degradation. Oncogene 2008, 27:4809-4819.
54. Kanazawa S., Soucek L., Evan G., Okamoto T., Peterlin B.M. c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis. Oncogene 2003, 22:5707-5711.
55. Vervoorts J., Luscher-Firzlaff J.M., Rottmann S., Lilischkis R., Walsemann G., Dohmann K., Austen M., Luscher B. Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP. EMBO Rep. 2003, 4:484-490.
56. Frank S.R., Schroeder M., Fernandez P., Taubert S., Amati B. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev. 2001, 15:2069-2082.
57. Wood M.A., McMahon S.B., Cole M.D. An ATPase/helicase complex is an essential cofactor for oncogenic transformation by c-Myc. Mol. Cell 2000, 5:321-330.
58. Fuchs M., Gerber J., Drapkin R., Sif S., Ikura T., Ogryzko V., Lane W.S., Nakatani Y., Livingston D.M. The p400 complex is an essential E1A transformation target. Cell 2001, 106:297-307.
59. von der Lehr N., Johansson S., Wu S., Bahram F., Castell A., Cetinkaya C., Hydbring P., Weidung I., Nakayama K., Nakayama K.I., Soderberg O., Kerppola T.K., Larsson L.G. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol. Cell 2003, 11:1189-1200.
60. Staller P., Peukert K., Kiermaier A., Seoane J., Lukas J., Karsunky H., Moroy T., Bartek J., Massague J., Hanel F., Eilers M. Repression of p15INK4b expression by Myc through association with Miz-1. Nat. Cell Biol. 2001, 3:392-399.
61. Brenner C., Deplus R., Didelot C., Loriot A., Vire E., De Smet C., Gutierrez A., Danovi D., Bernard D., Boon T., Pelicci P.G., Amati B., Kouzarides T., de Launoit Y., Di Croce L., Fuks F. Myc represses transcription through recruitment of DNA methyltransferase corepressor. EMBO J. 2005, 24:336-346.
62. Hurlin P.J., Queva C., Koskinen P.J., Steingrimsson E., Ayer D.E., Copeland N.G., Jenkins N.A., Eisenman R.N. Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation. EMBO J. 1995, 14:5646-5659.
63. Hurlin P.J., Queva C., Eisenman R.N. Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites. Genes Dev. 1997, 11:44-58.
64. Hassig C.A., Fleischer T.C., Billin A.N., Schreiber S.L., Ayer D.E. Histone deacetylase activity is required for full transcriptional repression by mSin3A. Cell 1997, 89:341-347.
65. Berns K., Hijmans E.M., Koh E., Daley G.Q., Bernards R. A genetic screen to identify genes that rescue the slow growth phenotype of c-myc null fibroblasts. Oncogene 2000, 19:3330-3334.
66. Nikiforov M.A., Chandriani S., O'Connell B., Petrenko O., Kotenko I., Beavis A., Sedivy J.M., Cole M.D. A functional screen for Myc-responsive genes reveals serine hydroxymethyltransferase, a major source of the one-carbon unit for cell metabolism. Mol. Cell. Biol. 2002, 22:5793-5800.
67. Shaffer A.L., Wright G., Yang L., Powell J., Ngo V., Lamy L., Lam L.T., Davis R.E., Staudt L.M. A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol. Rev. 2006, 210:67-85.
68. Margolin A.A., Palomero T., Sumazin P., Califano A., Ferrando A.A., Stolovitzky G. ChIP-on-chip significance analysis reveals large-scale binding and regulation by human transcription factor oncogenes. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:244-249.
69. Ben-Porath I., Thomson M.W., Carey V.J., Ge R., Bell G.W., Regev A., Weinberg R.A. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 2008, 40:499-507.
70. Ellwood-Yen K., Graeber T.G., Wongvipat J., Iruela-Arispe M.L., Zhang J., Matusik R., Thomas G.V., Sawyers C.L. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003, 4:223-238.
71. Adhikary S., Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol. 2005, 6:635-645.
72. Patel J.H., Loboda A.P., Showe M.K., Showe L.C., McMahon S.B. Analysis of genomic targets reveals complex functions of MYC. Nat. Rev. Cancer 2004, 4:562-568.
73. Nie Z., Hu G., Wei G., Cui K., Yamane A., Resch W., Wang R., Green D.R., Tessarollo L., Casellas R., Zhao K., Levens D. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 2012, 151:68-79.
74. Lin C.Y., Loven J., Rahl P.B., Paranal R.M., Burge C.B., Bradner J.E., Lee T.I., Young R.A. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012, 151:56-67.
75. Rahl P.B., Lin C.Y., Seila A.C., Flynn R.A., McCuine S., Burge C.B., Sharp P.A., Young R.A. c-Myc regulates transcriptional pause release. Cell 2010, 141:432-445.
76. Herkert B., Eilers M. Transcriptional repression: the dark side of myc. Genes Cancer 2010, 1:580-586.
77. Steiner P., Philipp A., Lukas J., Godden-Kent D., Pagano M., Mittnacht S., Bartek J., Eilers M. Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes. EMBO J. 1995, 14:4814-4826.
78. Beijersbergen R.L., Bernards R. Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. Biochim. Biophys. Acta 1996, 1287:103-120.
79. den Hollander J., Rimpi S., Doherty J.R., Rudelius M., Buck A., Hoellein A., Kremer M., Graf N., Scheerer M., Hall M.A., Goga A., von Bubnoff N., Duyster J., Peschel C., Cleveland J.L., Nilsson J.A., Keller U. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood 2010, 116:1498-1505.
80. Menssen A., Hermeking H. Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:6274-6279.
81. Warburg O. On the origin of cancer cells. Science (New York, N.Y.) 1956, 123:309-314.
82. Osthus R.C., Shim H., Kim S., Li Q., Reddy R., Mukherjee M., Xu Y., Wonsey D., Lee L.A., Dang C.V. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J. Biol. Chem. 2000, 275:21797-21800.
83. Le A., Lane A.N., Hamaker M., Bose S., Gouw A., Barbi J., Tsukamoto T., Rojas C.J., Slusher B.S., Zhang H., Zimmerman L.J., Liebler D.C., Slebos R.J., Lorkiewicz P.K., Higashi R.M., Fan T.W., Dang C.V. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 2012, 15:110-121.
84. Gordan J.D., Thompson C.B., Simon M.C. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007, 12:108-113.
85. O'Connell B.C., Cheung A.F., Simkevich C.P., Tam W., Ren X., Mateyak M.K., Sedivy J.M. A large scale genetic analysis of c-Myc-regulated gene expression patterns. J. Biol. Chem. 2003, 278:12563-12573.
86. Egle A., Harris A.W., Bouillet P., Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:6164-6169.
87. Zindy F., Eischen C.M., Randle D.H., Kamijo T., Cleveland J.L., Sherr C.J., Roussel M.F. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998, 12:2424-2433.
88. Love C., Sun Z., Jima D., Li G., Zhang J., Miles R., Richards K.L., Dunphy C.H., Choi W.W., Srivastava G., Lugar P.L., Rizzieri D.A., Lagoo A.S., Bernal-Mizrachi L., Mann K.P., Flowers C.R., Naresh K.N., Evens A.M., Chadburn A., Gordon L.I., Czader M.B., Gill J.I., Hsi E.D., Greenough A., Moffitt A.B., McKinney M., Banerjee A., Grubor V., Levy S., Dunson D.B., Dave S.S. The genetic landscape of mutations in Burkitt lymphoma. Nat. Genet. 2012, 44:1321-1325.
89. Sander S., Calado D.P., Srinivasan L., Kochert K., Zhang B., Rosolowski M., Rodig S.J., Holzmann K., Stilgenbauer S., Siebert R., Bullinger L., Rajewsky K. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 2012, 22:167-179.
90. Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W., Zhang M., Wright G., Shaffer A.L., Hodson D.J., Buras E., Liu X., Powell J., Yang Y., Xu W., Zhao H., Kohlhammer H., Rosenwald A., Kluin P., Muller-Hermelink H.K., Ott G., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Ogwang M.D., Reynolds S.J., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.C., Pittaluga S., Wilson W., Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012, 490:116-120.
91. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., Aldler H., Rattan S., Keating M., Rai K., Rassenti L., Kipps T., Negrini M., Bullrich F., Croce C.M. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:15524-15529.
92. Chang T.C., Yu D., Lee Y.S., Wentzel E.A., Arking D.E., West K.M., Dang C.V., Thomas-Tikhonenko A., Mendell J.T. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat. Genet. 2008, 40:43-50.
93. Zhang X., Zhao X., Fiskus W., Lin J., Lwin T., Rao R., Zhang Y., Chan J.C., Fu K., Marquez V.E., Chen-Kiang S., Moscinski L.C., Seto E., Dalton W.S., Wright K.L., Sotomayor E., Bhalla K., Tao J. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-cell lymphomas. Cancer Cell 2012, 22:506-523.
94. Zhang X., Chen X., Lin J., Lwin T., Wright G., Moscinski L.C., Dalton W.S., Seto E., Wright K., Sotomayor E., Tao J. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene 2012, 31:3002-3008.
95. Sampson V.B., Rong N.H., Han J., Yang Q., Aris V., Soteropoulos P., Petrelli N.J., Dunn S.P., Krueger L.J. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res. 2007, 67:9762-9770.
96. Chang T.C., Zeitels L.R., Hwang H.W., Chivukula R.R., Wentzel E.A., Dews M., Jung J., Gao P., Dang C.V., Beer M.A., Thomas-Tikhonenko A., Mendell J.T. Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3384-3389.
97. Bui T.V., Mendell J.T. Myc: Maestro of MicroRNAs. Genes Cancer 2010, 1:568-575.
98. Xiong L., Jiang W., Zhou R., Mao C., Guo Z. Identification and analysis of the regulatory network of Myc and microRNAs from high-throughput experimental data. Comput. Biol. Med. 2013, 43:1252-1260.
99. Eischen C.M., Weber J.D., Roussel M.F., Sherr C.J., Cleveland J.L. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999, 13:2658-2669.
100. Hemann M.T., Zilfou J.T., Zhao Z., Burgess D.J., Hannon G.J., Lowe S.W. Suppression of tumorigenesis by the p53 target PUMA. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:9333-9338.
101. Villunger A., Michalak E.M., Coultas L., Mullauer F., Bock G., Ausserlechner M.J., Adams J.M., Strasser A. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science (New York, N.Y.) 2003, 302:1036-1038.
102. Michalak E.M., Jansen E.S., Happo L., Cragg M.S., Tai L., Smyth G.K., Strasser A., Adams J.M., Scott C.L. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis. Cell Death Differ. 2009, 16:684-696.
103. Eischen C.M., Roussel M.F., Korsmeyer S.J., Cleveland J.L. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol. Cell. Biol. 2001, 21:7653-7662.
104. Vaux D.L., Cory S., Adams J.M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988, 335:440-442.
105. Bissonnette R.P., Echeverri F., Mahboubi A., Green D.R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992, 359:552-554.
106. Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:5413-5417.
107. Bhatia K.G., Gutierrez M.I., Huppi K., Siwarski D., Magrath I.T. The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors. Cancer Res. 1992, 52:4273-4276.
108. Mason K.D., Vandenberg C.J., Scott C.L., Wei A.H., Cory S., Huang D.C., Roberts A.W. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:17961-17966.
109. van Delft M.F., Wei A.H., Mason K.D., Vandenberg C.J., Chen L., Czabotar P.E., Willis S.N., Scott C.L., Day C.L., Cory S., Adams J.M., Roberts A.W., Huang D.C. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006, 10:389-399.
110. Kelly G.L., Grabow S., Glaser S.P., Fitzsimmons L., Aubrey B.J., Okamoto T., Valente L.J., Robati M., Tai L., Fairlie W.D., Lee E.F., Lindstrom M.S., Wiman K.G., Huang D.C., Bouillet P., Rowe M., Rickinson A.B., Herold M.J., Strasser A. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev. 2014, 28:58-70.
111. Srinivasan L., Sasaki Y., Calado D.P., Zhang B., Paik J.H., DePinho R.A., Kutok J.L., Kearney J.F., Otipoby K.L., Rajewsky K. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009, 139:573-586.
112. Richter J., Schlesner M., Hoffmann S., Kreuz M., Leich E., Burkhardt B., Rosolowski M., Ammerpohl O., Wagener R., Bernhart S.H., Lenze D., Szczepanowski M., Paulsen M., Lipinski S., Russell R.B., Adam-Klages S., Apic G., Claviez A., Hasenclever D., Hovestadt V., Hornig N., Korbel J.O., Kube D., Langenberger D., Lawerenz C., Lisfeld J., Meyer K., Picelli S., Pischimarov J., Radlwimmer B., Rausch T., Rohde M., Schilhabel M., Scholtysik R., Spang R., Trautmann H., Zenz T., Borkhardt A., Drexler H.G., Moller P., MacLeod R.A., Pott C., Schreiber S., Trumper L., Loeffler M., Stadler P.F., Lichter P., Eils R., Kuppers R., Hummel M., Klapper W., Rosenstiel P., Rosenwald A., Brors B., Siebert R. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat. Genet. 2012, 44:1316-1320.
113. Cato M.H., Chintalapati S.K., Yau I.W., Omori S.A., Rickert R.C. Cyclin D3 is selectively required for proliferative expansion of germinal center B cells. Mol. Cell. Biol. 2011, 31:127-137.
114. Peled J.U., Yu J.J., Venkatesh J., Bi E., Ding B.B., Krupski-Downs M., Shaknovich R., Sicinski P., Diamond B., Scharff M.D., Ye B.H. Requirement for cyclin D3 in germinal center formation and function. Cell Res. 2010, 20:631-646.
115. Fox C.J., Hammerman P.S., Cinalli R.M., Master S.R., Chodosh L.A., Thompson C.B. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev. 2003, 17:1841-1854.
116. Forshell L.P., Li Y., Forshell T.Z., Rudelius M., Nilsson L., Keller U., Nilsson J. The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas. Oncotarget 2011, 2:448-460.
117. Verbeek S., van Lohuizen M., van der Valk M., Domen J., Kraal G., Berns A. Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally. Mol. Cell. Biol. 1991, 11:1176-1179.
118. Lin Y.W., Beharry Z.M., Hill E.G., Song J.H., Wang W., Xia Z., Zhang Z., Aplan P.D., Aster J.C., Smith C.D., Kraft A.S. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood 2010, 115:824-833.
119. Allen J.D., Verhoeven E., Domen J., van der Valk M., Berns A. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene 1997, 15:1133-1141.
120. Soucek L., Whitfield J., Martins C.P., Finch A.J., Murphy D.J., Sodir N.M., Karnezis A.N., Swigart L.B., Nasi S., Evan G.I. Modelling Myc inhibition as a cancer therapy. Nature 2008, 455:679-683.
121. Choi P.S., van Riggelen J., Gentles A.J., Bachireddy P., Rakhra K., Adam S.J., Plevritis S.K., Felsher D.W. Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:17432-17437.
122. Savino M., Annibali D., Carucci N., Favuzzi E., Cole M.D., Evan G.I., Soucek L., Nasi S. The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. PLoS One 2011, 6:e22284.
123. Soucek L., Helmer-Citterich M., Sacco A., Jucker R., Cesareni G., Nasi S. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene 1998, 17:2463-2472.
124. Guo J., Parise R.A., Joseph E., Egorin M.J., Lazo J.S., Prochownik E.V., Eiseman J.L. Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z, E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother. Pharmacol. 2009, 63:615-625.
125. Prochownik E.V., Vogt P.K. Therapeutic targeting of Myc. Genes Cancer 2010, 1:650-659.
126. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., Kastritis E., Gilpatrick T., Paranal R.M., Qi J., Chesi M., Schinzel A.C., McKeown M.R., Heffernan T.P., Vakoc C.R., Bergsagel P.L., Ghobrial I.M., Richardson P.G., Young R.A., Hahn W.C., Anderson K.C., Kung A.L., Bradner J.E., Mitsiades C.S. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
127. Ott C.J., Kopp N., Bird L., Paranal R.M., Qi J., Bowman T., Rodig S.J., Kung A.L., Bradner J.E., Weinstock D.M. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012, 120:2843-2852.
128. Belkina A.C., Denis G.V. BET domain co-regulators in obesity, inflammation and cancer. Nat. Rev. Cancer 2012, 12:465-477.
129. Chapuy B., McKeown M.R., Lin C.Y., Monti S., Roemer M.G., Qi J., Rahl P.B., Sun H.H., Yeda K.T., Doench J.G., Reichert E., Kung A.L., Rodig S.J., Young R.A., Shipp M.A., Bradner J.E. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 2013, 24:777-790.
130. Loven J., Hoke H.A., Lin C.Y., Lau A., Orlando D.A., Vakoc C.R., Bradner J.E., Lee T.I., Young R.A. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153:320-334.
131. Whyte W.A., Orlando D.A., Hnisz D., Abraham B.J., Lin C.Y., Kagey M.H., Rahl P.B., Lee T.I., Young R.A. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 2013, 153:307-319.
132. Hnisz D., Abraham B.J., Lee T.I., Lau A., Saint-Andre V., Sigova A.A., Hoke H.A., Young R.A. Super-enhancers in the control of cell identity and disease. Cell 2013, 155:934-947.
133. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., Philpott M., Munro S., McKeown M.R., Wang Y., Christie A.L., West N., Cameron M.J., Schwartz B., Heightman T.D., La Thangue N., French C.A., Wiest O., Kung A.L., Knapp S., Bradner J.E. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
134. Nicodeme E., Jeffrey K.L., Schaefer U., Beinke S., Dewell S., Chung C.W., Chandwani R., Marazzi I., Wilson P., Coste H., White J., Kirilovsky J., Rice C.M., Lora J.M., Prinjha R.K., Lee K., Tarakhovsky A. Suppression of inflammation by a synthetic histone mimic. Nature 2010, 468:1119-1123.
135. Zuber J., Shi J., Wang E., Rappaport A.R., Herrmann H., Sison E.A., Magoon D., Qi J., Blatt K., Wunderlich M., Taylor M.J., Johns C., Chicas A., Mulloy J.C., Kogan S.C., Brown P., Valent P., Bradner J.E., Lowe S.W., Vakoc C.R. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.
136. Mertz J.A., Conery A.R., Bryant B.M., Sandy P., Balasubramanian S., Mele D.A., Bergeron L., Sims R.J. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:16669-16674.
137. Dawson M.A., Prinjha R.K., Dittmann A., Giotopoulos G., Bantscheff M., Chan W.I., Robson S.C., Chung C.W., Hopf C., Savitski M.M., Huthmacher C., Gudgin E., Lugo D., Beinke S., Chapman T.D., Roberts E.J., Soden P.E., Auger K.R., Mirguet O., Doehner K., Delwel R., Burnett A.K., Jeffrey P., Drewes G., Lee K., Huntly B.J., Kouzarides T. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478:529-533.
138. Chen L.S., Redkar S., Bearss D., Wierda W.G., Gandhi V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2009, 114:4150-4157.
139. Chen L.S., Redkar S., Taverna P., Cortes J.E., Gandhi V. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood 2011, 118:693-702.
140. Mikkers H., Nawijn M., Allen J., Brouwers C., Verhoeven E., Jonkers J., Berns A. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol. Cell. Biol. 2004, 24:6104-6115.
141. Nguyen M., Marcellus R.C., Roulston A., Watson M., Serfass L., Murthy Madiraju S.R., Goulet D., Viallet J., Belec L., Billot X., Acoca S., Purisima E., Wiegmans A., Cluse L., Johnstone R.W., Beauparlant P., Shore G.C. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19512-19517.
142. Spender L.C., Inman G.J. Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics. Mol. Cancer Res. 2012, 10:347-359.
143. Fry D.W., Harvey P.J., Keller P.R., Elliott W.L., Meade M., Trachet E., Albassam M., Zheng X., Leopold W.R., Pryer N.K., Toogood P.L. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 2004, 3:1427-1438.
144. Friedberg J.W., Mahadevan D., Cebula E., Persky D., Lossos I., Agarwal A.B., Jung J., Burack R., Zhou X., Leonard E.J., Fingert H., Danaee H., Bernstein S.H. Phase II study of alisertib, a selective aurora a kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2014, 32:44-50.
145. Le A., Cooper C.R., Gouw A.M., Dinavahi R., Maitra A., Deck L.M., Royer R.E., Vander Jagt D.L., Semenza G.L., Dang C.V. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:2037-2042.
146. Wahl M.L., Owen J.A., Burd R., Herlands R.A., Nogami S.S., Rodeck U., Berd D., Leeper D.B., Owen C.S. Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol. Cancer Ther. 2002, 1:617-628.
147. Bonnet S., Archer S.L., Allalunis-Turner J., Haromy A., Beaulieu C., Thompson R., Lee C.T., Lopaschuk G.D., Puttagunta L., Harry G., Hashimoto K., Porter C.J., Andrade M.A., Thebaud B., Michelakis E.D. A mitochondria-K+channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007, 11:37-51.
148. Fujiwara S., Kawano Y., Yuki H., Okuno Y., Nosaka K., Mitsuya H., Hata H. PDK1 inhibition is a novel therapeutic target in multiple myeloma. Br. J. Cancer 2013, 108:170-178.
149. Qing G., Li B., Vu A., Skuli N., Walton Z.E., Liu X., Mayes P.A., Wise D.R., Thompson C.B., Maris J.M., Hogarty M.D., Simon M.C. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell 2012, 22:631-644.
150. Niitsu N., Okamoto M., Miura I., Hirano M. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leuk. Off. J. Leuk. Soc. Am. Leuk. Res. Fund UK 2009, 23:777-783.
151. Bertrand P., Bastard C., Maingonnat C., Jardin F., Maisonneuve C., Courel M.N., Ruminy P., Picquenot J.M., Tilly H. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. Leuk. Off. J. Leuk. Soc. Am. Leuk. Res. Fund UK 2007, 21:515-523.
152. Avet-Loiseau H., Gerson F., Magrangeas F., Minvielle S., Harousseau J.L., Bataille R. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001, 98:3082-3086.
153. Shou Y., Martelli M.L., Gabrea A., Qi Y., Brents L.A., Roschke A., Dewald G., Kirsch I.R., Bergsagel P.L., Kuehl W.M. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:228-233.
154. Faderl S., O'Brien S., Pui C.H., Stock W., Wetzler M., Hoelzer D., Kantarjian H.M. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer 2010, 116:1165-1176.
155. De Jong D., Voetdijk B.M., Beverstock G.C., van Ommen G.J., Willemze R., Kluin P.M. Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma. N. Engl. J. Med. 1988, 318:1373-1378.
156. Young K.H., Xie Q., Zhou G., Eickhoff J.C., Sanger W.G., Aoun P., Chan W.C. Transformation of follicular lymphoma to precursor B-cell lymphoblastic lymphoma with c-myc gene rearrangement as a critical event. Am. J. Clin. Pathol. 2008, 129:157-166.
157. Slack G.W., Gascoyne R.D. MYC and aggressive B-cell lymphomas. Adv. Anat. Pathol. 2011, 18:219-228.
158. Setoodeh R., Schwartz S., Papenhausen P., Zhang L., Sagatys E.M., Moscinski L.C., Shao H. Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature. Int. J. Clin. Exp. Pathol. 2013, 6:155-167.
159. Put N., Van Roosbroeck K., Konings P., Meeus P., Brusselmans C., Rack K., Gervais C., Nguyen-Khac F., Chapiro E., Radford-Weiss I., Struski S., Dastugue N., Gachard N., Lefebvre C., Barin C., Eclache V., Fert-Ferrer S., Laibe S., Mozziconacci M.J., Quilichini B., Poirel H.A., Wlodarska I., Hagemeijer A., Moreau Y., Vandenberghe P., Michaux L. Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course. Ann. Hematol. 2012, 91:863-873.